173 related articles for article (PubMed ID: 36528660)
21. A conserved role for AMP-activated protein kinase in NGLY1 deficiency.
Han SY; Pandey A; Moore T; Galeone A; Duraine L; Cowan TM; Jafar-Nejad H
PLoS Genet; 2020 Dec; 16(12):e1009258. PubMed ID: 33315951
[TBL] [Abstract][Full Text] [Related]
22. Liver involvement in NGLY1 congenital disorder of deglycosylation.
Lipiński P; Cielecka-Kuszyk J; Socha P; Tylki-Szymańska A
Pol J Pathol; 2020; 71(1):66-68. PubMed ID: 32429657
[TBL] [Abstract][Full Text] [Related]
23. Reversibility of motor dysfunction in the rat model of NGLY1 deficiency.
Asahina M; Fujinawa R; Hirayama H; Tozawa R; Kajii Y; Suzuki T
Mol Brain; 2021 Jun; 14(1):91. PubMed ID: 34120625
[TBL] [Abstract][Full Text] [Related]
24. A
Talsness DM; Owings KG; Coelho E; Mercenne G; Pleinis JM; Partha R; Hope KA; Zuberi AR; Clark NL; Lutz CM; Rodan AR; Chow CY
Elife; 2020 Dec; 9():. PubMed ID: 33315011
[TBL] [Abstract][Full Text] [Related]
25. Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation.
Lam C; Ferreira C; Krasnewich D; Toro C; Latham L; Zein WM; Lehky T; Brewer C; Baker EH; Thurm A; Farmer CA; Rosenzweig SD; Lyons JJ; Schreiber JM; Gropman A; Lingala S; Ghany MG; Solomon B; Macnamara E; Davids M; Stratakis CA; Kimonis V; Gahl WA; Wolfe L
Genet Med; 2017 Feb; 19(2):160-168. PubMed ID: 27388694
[TBL] [Abstract][Full Text] [Related]
26. Assay for the peptide:N-glycanase/NGLY1 and disease-specific biomarkers for diagnosing NGLY1 deficiency.
Hirayama H; Suzuki T
J Biochem; 2022 Feb; 171(2):169-176. PubMed ID: 34791337
[TBL] [Abstract][Full Text] [Related]
27. An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency.
Hope KA; Berman AR; Peterson RT; Chow CY
PLoS Genet; 2022 Jun; 18(6):e1010228. PubMed ID: 35653343
[TBL] [Abstract][Full Text] [Related]
28. Delineating the epilepsy phenotype of NGLY1 deficiency.
Levy RJ; Frater CH; Gallentine WB; Phillips JM; Ruzhnikov MR
J Inherit Metab Dis; 2022 May; 45(3):571-583. PubMed ID: 35243670
[TBL] [Abstract][Full Text] [Related]
29. Ocular features of NGLY1 deficiency from a prospective longitudinal cohort.
Frater CH; Ruzhnikov MRZ; Beres S; Alcorn D; Shue A; Levy RJ
J AAPOS; 2024 Jun; 28(3):103925. PubMed ID: 38697387
[TBL] [Abstract][Full Text] [Related]
30. N-Glycanase 1 Transcriptionally Regulates Aquaporins Independent of Its Enzymatic Activity.
Tambe MA; Ng BG; Freeze HH
Cell Rep; 2019 Dec; 29(13):4620-4631.e4. PubMed ID: 31875565
[TBL] [Abstract][Full Text] [Related]
31. An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene.
Yang S; Cheng YS; Li R; Pradhan M; Hong J; Beers J; Zou J; Liu C; Might M; Rodems S; Zheng W
Stem Cell Res; 2019 Aug; 39():101496. PubMed ID: 31326749
[TBL] [Abstract][Full Text] [Related]
32. Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9.
Pavlinov I; Farkhondeh A; Yang S; Xu M; Cheng YS; Beers J; Zou J; Liu C; Might M; Rodems S; Baumgärtel K; Zheng W
Stem Cell Res; 2021 Oct; 56():102554. PubMed ID: 34619643
[TBL] [Abstract][Full Text] [Related]
33. Aspartylglycosamine is a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation.
Haijes HA; de Sain-van der Velden MGM; Prinsen HCMT; Willems AP; van der Ham M; Gerrits J; Couse MH; Friedman JM; van Karnebeek CDM; Selby KA; van Hasselt PM; Verhoeven-Duif NM; Jans JJM
Mol Genet Metab; 2019 Aug; 127(4):368-372. PubMed ID: 31311714
[TBL] [Abstract][Full Text] [Related]
34. Intranasal oxytocin suppresses seizure-like behaviors in a mouse model of NGLY1 deficiency.
Makita Y; Asahina M; Fujinawa R; Yukitake H; Suzuki T
Commun Biol; 2024 Apr; 7(1):460. PubMed ID: 38649481
[TBL] [Abstract][Full Text] [Related]
35. Comparative proteomics reveals elevated CCN2 in NGLY1-deficient cells.
Hetz R; Magaway C; Everett J; Li L; Willard BB; Freeze HH; He P
Biochem Biophys Res Commun; 2022 Dec; 632():165-172. PubMed ID: 36209585
[TBL] [Abstract][Full Text] [Related]
36. Progressive myoclonic epilepsy as an expanding phenotype of NGLY1-associated congenital deglycosylation disorder: A case report and review of the literature.
Sonoda Y; Fujita A; Torio M; Mukaino T; Sakata A; Matsukura M; Yonemoto K; Hatae K; Ichimiya Y; Chong PF; Ochiai M; Wada Y; Kadoya M; Okamoto N; Murakami Y; Suzuki T; Isobe N; Shigeto H; Matsumoto N; Sakai Y; Ohga S
Eur J Med Genet; 2024 Feb; 67():104895. PubMed ID: 38070824
[TBL] [Abstract][Full Text] [Related]
37. Variants in NGLY1 lead to intellectual disability, myoclonus epilepsy, sensorimotor axonal polyneuropathy and mitochondrial dysfunction.
Panneman DM; Wortmann SB; Haaxma CA; van Hasselt PM; Wolf NI; Hendriks Y; Küsters B; van Emst-de Vries S; van de Westerlo E; Koopman WJH; Wintjes L; van den Brandt F; de Vries M; Lefeber DJ; Smeitink JAM; Rodenburg RJ
Clin Genet; 2020 Apr; 97(4):556-566. PubMed ID: 31957011
[TBL] [Abstract][Full Text] [Related]
38. ELISA-based highly sensitive assay system for the detection of endogenous NGLY1 activity.
Fujihira H; Sato K; Nishiuchi Y; Murase T; Matsuda Y; Yoshida Y; Kamei T; Suzuki T
Biochem Biophys Res Commun; 2024 May; 710():149826. PubMed ID: 38581946
[TBL] [Abstract][Full Text] [Related]
39. Unexplained death in patients with NGLY1 mutations may be explained by adrenal insufficiency.
van Keulen BJ; Rotteveel J; Finken MJJ
Physiol Rep; 2019 Feb; 7(3):e13979. PubMed ID: 30740912
[TBL] [Abstract][Full Text] [Related]
40. NGLY1 deficiency-A rare congenital disorder of deglycosylation.
Lipari Pinto P; Machado C; Janeiro P; Dupont J; Quintas S; Sousa AB; Gaspar A
JIMD Rep; 2020 May; 53(1):2-9. PubMed ID: 32395402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
